Core Viewpoint - RxSight, Inc. is set to participate in the J.P. Morgan Healthcare Conference, highlighting its commitment to advancing ophthalmic medical devices for cataract surgery patients [1][2]. Company Overview - RxSight, Inc. specializes in ophthalmic medical devices aimed at providing customized vision solutions for patients post-cataract surgery [3]. - The company's flagship product, the RxSight Light Adjustable Lens system, is the first and only commercially available intraocular lens technology that can be adjusted after surgery, allowing for tailored vision correction [3]. Event Participation - Management will present at the J.P. Morgan Healthcare Conference on January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time, with a live and archived webcast available for interested parties [2].

Core Insights - The article emphasizes the importance of disciplined risk management in investment strategies, advocating for a barbell approach that allocates 90% to safe assets and 10% to high-growth opportunities [1] DCF Model Assumptions - The valuation model assumes free cash flow will grow at a constant annual rate over the next eight years, with each year's projected cash flow discounted back to present value using a fixed discount rate derived from the Capital Asset Pricing Model (CAPM) [1] - A terminal value is calculated by projecting free cash flow into the ninth year, assuming it continues to grow at the same rate, and applying a perpetual growth rate using the Gordon Growth Model [1] - Key assumptions include constant growth and discount rates over time, with the discount rate exceeding the perpetual growth rate to ensure a finite terminal value [1]

Investors might want to bet on RxSight, Inc. (RXST) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a ch ...

RxSight, Inc. (NASDAQ:RXST) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Conference Call Participants Lilia Lozada - J.P. Morgan Iseult McMahon - BTIG Lei Huang - Wells Fargo Craig Bijou - Bank of America Young Li - Jefferies Tom Stephan - Stifel Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & ...

RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the company has surpassed consensus ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 Identification No.) (I.R.S.Employer (State or other jurisdiction of incorporationororganization) RxSIGHT, INC. (Exact N ...

Exhibit 99.1 RXSIGHT, INC. REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) – November 7, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights • Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: • The s ...

ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference cal ...

ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference - Fireside Chat: Wednesday, September 4, 2024, at 9:15 a.m. ET in New York City, NY Wells Fargo 2024 Healthcare Conference - Fireside Chat: Thur ...

52 Week Range 66.54 20.66 Day Range 52.42 51.03 ● eps (fwd) -0.82 PE . Div Rate . Yield Short Interest 5.02% Market Cap $2.07B Volume 172,598 Prev. Close $52.16 David Trood RtsSight, Inc. (NASDAQ:RXST) is a pioncering medical technology company dedicated to transforming the cataract surgery landscape. The company's flagship rectual online (10,000 (0.101) posted, is the first and only FDA-approved premium intraocular clargest, mocendar. margesty, anto compary, v mbosmper in viagampe vindeming m and unparalle ...